

Programme

Wed 23 Oct

11:50

Oral presentation

NIDA International Program Research Update

11:50 to 13:20
Auditorium VI
Tom Clarke

Oral presentation

Managing Benzodiazepine Dependence and High-Risk Use with Opiates: A feasibility study of a Co- produced Intervention

11:50 to 13:20
Auditorium II
Catriona Matheson

Oral presentation

Treatment of benzodiazepine withdrawal through taper dosing is most successful when it lasts less than 6 months.

11:50 to 13:20
Auditorium II
Alert Drishti

Oral presentation

Understanding the research capacity of Australian alcohol and other drug services

11:50 to 13:20
Auditorium VI
Robert Stirling

Oral presentation

Report from LX24 side event - Strengthening networks and sharing innovation in practices on

Oral presentation

The effectiveness of naloxone in reversing opioid overdose: The European naloxone

Oral presentation

A global perspective on the emotions associated with chemsex practice to better support the community

research and surveillance in the drugs field

11:50 to 13:20
Auditorium VI
Vickna Kasinather
Charles Parry

outcome research study (NalPORS)

11:50 to 13:20
Auditorium II
Nicola Metrebian

11:50 to 13:20
Auditorium IV
Yannick Gaudette

Oral presentation

Addiction and financial burden: Longitudinal 6-time point analysis of risk factors for debt enforcement in Finland

11:50 to 13:20
Room 5B
Atte Oksanen

Oral presentation

Addressing gender, diversity, and precarity: participatory research to transform addiction services in Canada

11:50 to 13:20
Auditorium IV
Karine Bertrand

Oral presentation

Bipolar disorder and severe poisoning due to medicines or illicit substances

11:50 to 13:20
Auditorium VII
Aleksi Hamina

Oral presentation

Bringing law enforcement officers (LEO) closer to other agents of prevention: A UNODC Guiding Document

11:50 to 13:20
Room 5A
Ali Yassine

Oral presentation

Chemsex Professional Training Program in Catalonia

11:50 to 13:20
Auditorium IV
Elena Adán Ibáñez

Oral presentation

Children AMplified Prevention Services (CHAMPS): Amplify Children Resilience through a comprehensive prevention system

11:50 to 13:20
Room 5A
Ali Yassine

Oral presentation

Cultural safety and telecare. A systematic scoping review and sector survey

11:50 to 13:20
Auditorium III
Rodrigo Ramalho

Oral presentation

Drug Consumption Rooms in Europe. Operational characteristics, capacities, services and its associated factors.

11:50 to 13:20
Auditorium III
Joana Moura

Oral presentation

Enhanced self-efficacy in HCV management: educating a multidisciplinary drug and alcohol workforce in Europe and Canada

11:50 to 13:20
Room 5C
Emma Day

Oral presentation

Enhancing Capacity for Comprehensive Drug Use Response in Humanitarian Settings

11:50 to 13:20

Oral presentation

Exploring Australian addiction workers' views on inclusive treatment for transgender and gender diverse (TGD) clients.

11:50 to 13:20
Room 5C
Nic Robinson-Griffith

Oral presentation

Foundations of Prevention Science and Practice Curriculum: Providing Technical Assistance through Training

11:50 to 13:20
Room 5C
Maria Paula Luna Jimenez

Oral presentation

Gambling Disorder and Work Disability: A National Registry Study in Sweden

11:50 to 13:20
Room 5B
Viktor Mansson

Oral presentation

Hazardous substance use and mental health among refugees in shared accommodations - a mixed-methods study

11:50 to 13:20
Auditorium VII
Miriam Lorenz

Oral presentation

Lisdexamfetamine in the treatment of methamphetamine dependence, a randomised controlled trial

11:50 to 13:20
Auditorium II
Nadine Ezard

Oral presentation

Modelling the wider socio-economic costs of problematic opioid use in the UK

11:50 to 13:20
Auditorium VIII
George Keel

Oral presentation

Prevalence of opioid dependence in Scotland, 2015-2020: results from a Multi Parameter Estimation of Prevalence model

11:50 to 13:20
Auditorium VIII
Hayley Jones

Oral presentation

Problem Gambling Among Criminal Sanction Clients: Project Overview

11:50 to 13:20
Room 5B
Sari Castrén

Oral presentation

Scaling up Harm Reduction: Results of the 3-year Take-Home Naloxone project NALtrain in Germany.

11:50 to 13:20
Room 5C
Simon Fleißner

Oral presentation

Substance Use, Sexual Pleasure and Recovery among gbMSM: Addressing Sexual Satisfaction in Addiction Interventions

11:50 to 13:20
Auditorium IV
Maxime Blanchette

Oral presentation

Oral presentation

Oral presentation

Suicide-related service presentations following residential treatment for substance use disorders: a data linkage study

11:50 to 13:20
Auditorium VII
Calvert Tisdale

Oral presentation

The reciprocal effects of gambling expenditure and crime.

11:50 to 13:20
Room 5B
Don Weatherburn

Oral presentation

Twenty-one years of heroin-related mortality in Australia: Joinpoint regression analysis of trends by age and gender

11:50 to 13:20
Auditorium VIII
Amanda Roxburgh

Oral presentation

The gendered impacts of drug stigma - a qualitative study with 10 street-involved women who use drugs in Porto

11:50 to 13:20
Auditorium IV
Cristiana Vale Pires

Oral presentation

The role of physical activity in preventing relapse: the perception of participants

11:50 to 13:20
Auditorium III
Florence Piché

Oral presentation

Underestimate of deaths due to specific opioids in England and Wales for a decade

11:50 to 13:20
Auditorium VIII
Shuoqi Chen

The impact of severe mental illness on treatment retention and all-cause mortality of people in opioid agonist treatment

11:50 to 13:20
Auditorium VII
Nicola Jones

Oral presentation

The Staying Safe Programme: A new online education approach to reducing drug related harm for university students

11:50 to 13:20
Room 5A
Adam Winstock

Oral presentation

User experiences of a digital intervention among individuals on opioid use disorder treatment in Kenya

11:50 to 13:20
Auditorium III
Sarah Kanana Kiburi

“Good health has nothing to do with alcohol”: perceptions and impacts of a French alcohol prevention campaign

11:50 to 13:20
Room 5A
Guillemette Quatremere

14:20

Oral presentation

Engaging governments and providing technical assistance

14:20 to 15:50
Room 5C
Goodman Sibeko

Oral presentation

Why is a gender perspective needed in the drug field? Insight from the latest European drugs data.

14:20 to 15:50
Auditorium VIII
Linda Montanari

Oral presentation

Regional activity undertaken by the African Union

14:20 to 15:50
Room 5C
Abel Basutu

Oral presentation

Structure and predictive validity of alcohol use disorder recovery domains in young adulthood

14:20 to 15:50
Auditorium II
George Richardson

Oral presentation

An 11-year analysis of alcohol-related emergency

Oral presentation

Developing the Addiction Workforce in Africa:

Oral presentation

Building a substance use workforce network in

department presentations by young people, from an EU hospital setting

14:20 to 15:50
Auditorium II
Marie Hyland

Progress and Issues

14:20 to 15:50
Room 5C
Kevin Mulvey

Africa

14:20 to 15:50
Room 5C
Rasha Abi Hana

Oral presentation

Heavy episodic drinking among French adolescents between 2005 and 2022: a gender perspective.

14:20 to 15:50
Auditorium II
Eric Janssen

Oral presentation

Bridging the Gap: Exploring School Survey Data in Drug Policy and Prevention - Insights from the ESPAD-MedSPAD Project

14:20 to 15:50
Room 5A
Elisa Benedetti

Oral presentation

Changes in cannabis potency and cannabis-related harms: A 22-year ecological study in Denmark

14:20 to 15:50
Room 1.07
Kristine Rømer Thomsen

Oral presentation

Deficits in cognitive functions across different types of Internet-use disorders: Gender-related differences

14:20 to 15:50
Room 5B
Silke M. Müller

Oral presentation

Developing and operationalising a multi-component drug outreach service for young people aged 16-25 in England

14:20 to 15:50
Room 5A

Oral presentation

Digital components in interventions aiming to reduce or prevent alcohol use among young people: A scoping review.

14:20 to 15:50

Oral presentation

Drug-induced homicide laws in the US: current trends, stakeholder opinions, and public health impacts

14:20 to 15:50
Auditorium VI
Jennifer Carroll

Oral presentation

Effect of acute stress on cue reactivity and craving in online buying-shopping disorder and social network use disorder

14:20 to 15:50
Room 5B
Elisa Wegmann

Oral presentation

Gender Compression Over Time in Measures of Cannabis Use by Age and Cohort in the United States

14:20 to 15:50
Auditorium VIII
Michael Vuolo

Oral presentation

Global coverage of interventions to prevent and manage injecting drug use related harms in prisons: a systematic review

14:20 to 15:50
Auditorium VI
Thomas Santo Jr.

Oral presentation

Judge Demographics and Their Impact on Sentencing of Drug Crimes

14:20 to 15:50
Auditorium IV
Sarah Henry Davis

Oral presentation

Levels of toxicants among people who vape, smoke, dual use, or do neither among people with and without psychosis.

14:20 to 15:50

Oral presentation

Leximetric analysis of drug laws and evaluation of outcomes: cross-country analyses approach

14:20 to 15:50
Auditorium IV
Carla Rossi

Auditorium VII
Eve Taylor

Oral presentation

MATPACT: An innovative approach to finding Scotland's forgotten generation

14:20 to 15:50
Auditorium VI
Marion Gillies

Oral presentation

Navigating the Shift: Understanding the Dynamics of Cannabis Use in Germany Amidst Legalization Prospects

14:20 to 15:50
Auditorium IV
Sally Olderbak

Oral presentation

Pharmacology of generic ban-evading synthetic cannabinoid receptor agonists: are new compounds spicing up the market?

14:20 to 15:50
Room 1.07
Marie Deventer

Oral presentation

Policy and Practice Responses to Drug-Related Deaths: Governance issues in English and Welsh Prisons, 2015-2021

14:20 to 15:50
Auditorium VI
Karen Duke

Oral presentation

Proximal and distal cues in social network use disorder: the interplay of cue-reactivity, craving, and acute stress

14:20 to 15:50
Room 5B
Annica Kessling

Oral presentation

Psychological distress, tobacco

Oral presentation

Risk and protective factors in

Oral presentation

Risk factors for the gambling, smoking and

smoking and alcohol use: a population survey in Great Britain

14:20 to 15:50
Auditorium VII
Erikas Simonavičius

Oral presentation

Smokers' careers and mental health: overlapping perspectives on cannabis and tobacco use

14:20 to 15:50
Auditorium VII
Joana Sisternas-Tusell

Oral presentation

The Neurobiological and Neuropsychological Link Between Gambling Disorder and

adolescents: adapting Communities that Care Youth Survey for Portuguese context

14:20 to 15:50
Room 5A
Susana Henriques

Oral presentation

Smoking and nicotine use behaviours among women of reproductive age: a ten-year population study in England

14:20 to 15:50
Auditorium VIII
Sharon Cox

Oral presentation

The perspective of transgender and non-binary people on their substance use trajectories

alcohol consumption triad: an observational study in Portuguese adolescents

14:20 to 15:50
Room 5A
Pedro Ramos

Oral presentation

The challenge of cannabis quantification: from theory to practice

14:20 to 15:50
Room 1.07
Cláudia Sousa-Reis

Oral presentation

The effects of legislative measures for 3-MMC in the Netherlands on drug sample composition and self-reported effects.

14:20 to 15:50
Auditorium IV
Pieter Oomen

Substance Abuse

14:20 to 15:50
Room 5B
Gisela Simões

and resilience processes

14:20 to 15:50
Auditorium VIII
Abdelhakim Missoum

16:00

Oral presentation

Increased hepatitis C and HIV incidence among people who inject drugs in Montreal, Canada, 2011-2023

16:00 to 17:30
Auditorium IV
Sarah Larney

Oral presentation

Alcohol Mis(Use) among Migrants, Asylum-seekers and Refugees: state-of-the-art

16:00 to 17:30
Auditorium II
Maria Pires Cameira

Oral presentation

Canada synthetic opioids situation

16:00 to 17:30
Auditorium VIII
Pam Kent

Oral presentation

Emerging drug trends - what are the issues and how can we strengthen preparedness

16:00 to 17:30
Auditorium VIII
Paul Griffiths

Oral presentation

Harm reduction interventions and Indigenous peoples: The first Managed Alcohol Program in Montreal

16:00 to 17:30
Auditorium II
Rossio Motta-Ochoa

Oral presentation

Predictors of outcome in individuals with alcohol use disorder and a treatment goal of controlled drinking

16:00 to 17:30
Auditorium II
Anders Hammarberg

Oral presentation

The U.S. international perspective including the Global Coalition

16:00 to 17:30
Auditorium VIII
Charlotte Sisson

Oral presentation

Crafting the international standard: Establishing and

**implementing
core outcome
measures for
alcohol brief
interventions**

16:00 to 17:30
Auditorium II
Gillian W. Shorter

Oral presentation

**US experience
with synthetic
drugs**

16:00 to 17:30
Auditorium VIII
Christopher M. Jones

Oral presentation

**"Boxing
Clever Cork
saved my
life";: an
evaluation of
an Irish early
addiction
recovery
initiative**

16:00 to 17:30
Auditorium III
Rebekah Brennan

Oral presentation

**A Safer
Downtown for
All: Including
People Who
Use Drugs in
the Solutions
to Social
Disorder**

16:00 to 17:30
Auditorium III
Rob Boyd

Oral presentation

**Acute drug-
toxicity
presentations
involving crack
cocaine to
Euro-DEN Plus
sentinel
hospitals in
Europe from
2014-2022**

16:00 to 17:30
Room 5A
Isabelle Giraudon

Oral presentation

**Antipsychotics
and relapse
risk in persons
with first-
episode
psychosis and**

Oral presentation

**Associations of
alcohol
consumption
with long-term
mortality of
ART-naïve**

Oral presentation

**Building
Capacity For
Future
Evaluation of
Residential
Treatment for**

**co-occurring
cannabis use
disorder**

16:00 to 17:30
Auditorium VII
Heidi Taipale

Oral presentation

**Cannabinoid
Use Experience
among
inpatients with
psychotic
symptoms - A
Cross-Sectional
study in a
Portuguese
Hospital**

16:00 to 17:30
Auditorium VII
Carolina Afonso Romano

**persons
seeking HIV
care.**

16:00 to 17:30
Auditorium IV
Daniel Fuster

Oral presentation

**Challenges and
support needs
among persons
with a
migration
background
who use drugs
in four
metropolitan
cities**

16:00 to 17:30
Room 5C
Wouter Vanderplasschen

**People
Experiencing
Homelessness
and Addiction**

16:00 to 17:30
Auditorium III
Ed Addison

Oral presentation

**Considering
the prevention
workforce: a
study on
practitioner
needs when
recommending
substance use
interventions**

16:00 to 17:30
Room 1.06
Natalie Blackburn

Oral presentation

**Decentralized
consultation
for infectious
diseases with
at-risk
populations:
preliminary
results**

16:00 to 17:30
Auditorium IV
Paulo Caldeira

Oral presentation

**Documenting
major shifts in
methamphetamine
and heroin
prices and
purity in
metropolitan
and rural**

Oral presentation

**Drug markets
and financial
flows:
underground
banking in the
Netherlands**

16:00 to 17:30
Auditorium VI

Oral presentation

**Drug poisoning
deaths of
under 30-year-
olds - Key
issues in the
cause of death
investigation
documents**

Victoria, Australia

16:00 to 17:30
Auditorium VI
Kasun Rathnayake

Nienke Liebrechts

16:00 to 17:30
Room 5A
Sanna Rönkä

Oral presentation

**Drug use and
(non-)use of
addiction
treatment by
women in
French
Guyana:
gender and
migration
effects**

16:00 to 17:30
Room 5C
Estelle Filipe

Oral presentation

**Effects of
recreational
cannabis
versus black
market: A
randomized
controlled trial
in Switzerland
(WEED CARE)**

16:00 to 17:30
Auditorium VI
Lavinia Baltes

Oral presentation

**Evaluating and
comparing
health quality
for addiction
treatment in
the Lazio
region, Italy**

16:00 to 17:30
Room 1.06
Antonella Camposeragna

Oral presentation

**How do purity
and price of
cocaine affect
consumption in
Austria?**

16:00 to 17:30
Auditorium VI
Birgit Priebe

Oral presentation

**How do you
make it work?
A pragmatic
framework for
the Sustained
Uptake of
Service
Innovations
(SUSI).**

16:00 to 17:30
Room 1.06
Catherine Foley

Oral presentation

**Instruments
assessing
Gaming
Disorder in
children and
adolescents - A
systematic
review of
psychometric
properties**

16:00 to 17:30
Room 5B
Samantha Schlossarek

Oral presentation

Oral presentation

Oral presentation

Oral presentation

Migrants in the criminal justice system: A qualitative understanding of the role of substance use in their lives

16:00 to 17:30
Room 5C
Marjolein De Pau

Oral presentation

Mortality among first-time opioid agonist therapy patients in Austria, 2002-2021: A national retrospective cohort study

16:00 to 17:30
Room 5A
Tanja Schwarz

Oral presentation

Mothers receiving substance use treatment involved in care proceedings: A record linkage cohort study

16:00 to 17:30
Room 5A
Martha Canfield

Oral presentation

Planning and Monitoring drug and alcohol treatment in Denmark. The MapPlan project.

16:00 to 17:30
Room 1.06
Mads Uffe Pedersen

Oral presentation

Psychoactive Substance Use Among Russian Migrants Relocated to Georgia Following the 2022 Ukrainian Invasion

16:00 to 17:30
Room 5C
David Otiashvili

Oral presentation

Real-world effectiveness of antipsychotic medication in relapse prevention after cannabis-induced psychosis

16:00 to 17:30
Auditorium VII
Antti Mustonen

Oral presentation

Refugees & drug use in Belgium: A national study on drug-related intervention needs in the reception setting (DrugInt)

16:00 to 17:30
Room 5C
Charlotte de Kock

Oral presentation

Oral presentation

Oral presentation

Screening Measures on Internet Use Disorders in Children and Adolescents - A Delphi Study

16:00 to 17:30
Room 5B
Hans-Juergen Rumpf

Superiority and cost-effectiveness of Individual Placement and Support for people with alcohol and drug dependence

16:00 to 17:30
Auditorium III
John Marsden

The Gaming Disorder Identification Test (GADIT) - A screening tool for Gaming Disorder based on ICD-11

16:00 to 17:30
Room 5B
Gary Chan

Oral presentation

The Problematic Behaviour Scale (PBS-10): psychometric characteristics and cut-offs using Swiss national survey data

16:00 to 17:30
Room 5B
Sebastian Mader

Oral presentation

“Into a whirlwind”: Navigating psychosis and anti-psychotic treatment among youth entrenched in an urban drug scene

16:00 to 17:30
Auditorium VII
Trevor Goodyear

Oral presentation

“They kicked me out of hospital twice”: barriers and facilitators accessing care with an injecting-related infection

16:00 to 17:30
Auditorium IV
Samantha Colledge-Frisby

Oral presentation

Application of the International Standards for the Treatment of Drug Use Disorders and the Key Quality Standards for service appraisal

17:50 to 19:20
Auditorium II
Anja Busse

Oral presentation

International Consortium on Quality in Substance Use Disorders Treatment

17:50 to 19:20
Auditorium II
Rita Notarandrea

Oral presentation

Insights from the Recipient of the first ICQ Quality Seal Award

17:50 to 19:20
Auditorium II
Michael W. Johnson

Oral presentation

PIQAT: Program for International Quality Assurance in Treatment

17:50 to 19:20
Auditorium II
Mariano Montenegro

Oral presentation

(De)criminalisation of drug possession as a litmus test of national drug policy? Experience from the Czech Republic

17:50 to 19:20
Auditorium VI
Petr Zeman

Oral presentation

20-year trends in Australian methamphetamine related deaths: An age-period-cohort-interaction analysis

17:50 to 19:20
Auditorium IV
Oisin Stronach

Oral presentation

A Collaborative Approach to New Drug Identification in an Emerging Drug Early Warning System

17:50 to 19:20
Auditorium III
Donna Papsun

Oral presentation

Achieving universal health coverage of opioid agonist treatment in Norway: a

Oral presentation

Adolescents spending time with their parents: does it matter to prevent risky and addictive

cost-utility analysis

17:50 to 19:20
Room 5B
Prayash Chaudhary

behaviors?

17:50 to 19:20
Room 5A
Ina Koning

Oral presentation

AN IMPLEMENTATION SCIENCE EVALUATION OF SCOTLAND'S FIRST HEROIN ASSISTED TREATMENT (HAT) FACILITY

17:50 to 19:20
Room 5B
Andrew McAuley

Oral presentation

Assessing quality of substance use treatment in legal settings: lessons from United States drug courts

17:50 to 19:20
Auditorium VI
Steven Belenko

Oral presentation

Codeine, oxycodone, and tramadol prescription prior to overdose deaths compared to toxicological findings

17:50 to 19:20
Auditorium IV
Hilde Edvardsen

Oral presentation

Comorbidity of substance use disorders and other mental health disorders: towards a common European approach

17:50 to 19:20
Auditorium VII
Marta Torrens

Oral presentation

Development of a mobile neuroscience- informed psychoeducation program for resilience and substance use

Oral presentation

Effects of cannabis use timing and formulation on sleep among young adults who report high-intensity

Oral presentation

Emergence of semi-synthetic cannabinoids in Europe - a perspective from the European Union Early

prevention

17:50 to 19:20
Room 5A
Jasmin Vassileva

Oral presentation

Examining Associations Between Alcohol and Cannabis Simultaneous and Concurrent Co-Use and Mental Health Outcomes

17:50 to 19:20
Auditorium VII
Bradley Conner

Oral presentation

Medical use of psychedelic substances: EUDA's monitoring of key developments

17:50 to 19:20
Auditorium VIII
Alexander Söderholm

Oral presentation

alcohol use

17:50 to 19:20
Auditorium VII
Elizabeth R. Aston

Oral presentation

Exploring social-environmental factors in recovery and reintegration of substance-related disorders: a scoping review

17:50 to 19:20
Room 5A
Mariana Vieira

Oral presentation

Monitoring intravenous drugs use in Spain through syringe residue analysis

17:50 to 19:20
Auditorium IV
Carlos Pernas-Fraguela

Oral presentation

Warning System

17:50 to 19:20
Auditorium III
Rachel Christie

Oral presentation

Heavy drinking among 'sober generation' youth: a longitudinal study

17:50 to 19:20
Room 5C
Marit Edland-Gryt

Oral presentation

Law Enforcement Encounters and Decriminalization Gaps: Insights from People Who Use Drugs in Oregon Post-Measure 110

17:50 to 19:20
Auditorium VI
Morgan Godvin

Oral presentation

Motivations for cocaine use: relation with drug use patterns, risks and how this informs prevention

17:50 to 19:20
Room 5C
Eva Blomme

Oral presentation

Motivations underlying co-use of benzodiazepines and opioids in the UK: a qualitative study

17:50 to 19:20
Room 5C
Gaby Vojt

Parents aren't out of the picture: Parent factors are linked with heavy episodic drinking among high school students

17:50 to 19:20
Room 5A
Lotte Vallentin-Holbech

Police drug diversion in England and Wales: Findings from a realist process evaluation

17:50 to 19:20
Auditorium VI
Alex Beerjeraz

Oral presentation

Quantifying and expanding alternatives to arrest for use and possession offences for illicit drugs

17:50 to 19:20
Auditorium VI
Caitlin Hughes

Oral presentation

Reduced health care utilization after entering opioid agonist treatment; change in mental and somatic health domains

17:50 to 19:20
Room 5B
Thomas Clausen

Oral presentation

Route-Dependent Subjective Effects of Medical Heroin in HAT: Implications for Treatment Trajectories

17:50 to 19:20
Room 5B
Silvana De Pirro

Oral presentation

Synthetic cathinones in drug-related deaths - an alarming issue

Oral presentation

Self-therapeutic use of psilocybin, MDMA and ketamine among Dutch nightlife attendees.

17:50 to 19:20
Auditorium VIII
Frederiek Schutten

Oral presentation

The relationship between self-reported childhood

or triviality?

17:50 to 19:20
Auditorium III
Ilkka Ojanperä

maltreatment and mental health in substance use disorders

17:50 to 19:20
Auditorium VII
Aleksander Hagen Erga

Oral presentation

The U.S. Psilocybin Landscape: Policy Evolution and Nationally Representative Insights

17:50 to 19:20
Auditorium VIII
Beau Kilmer

Oral presentation

Trends in GHB use and harms in Australia

17:50 to 19:20
Auditorium III
Rachel Sutherland

Oral presentation

What are the reasons for injecting methadone? A qualitative study among people who inject drugs in Barcelona

17:50 to 19:20
Auditorium IV
Gabriela Barbaglia

Oral presentation

‘Russian Roulette’: how do people who co-use benzodiazepines and opioids experience the absence of harm reduction?

17:50 to 19:20
Room 5C
Hannah Poulter

Thu 24 Oct

11:50

Oral presentation

Crisis in the race to

Oral presentation

Long-acting injectable

Oral presentation

Neurobiological Markers of

**hepatitis C
elimination:
modelling
futures without
disease**

11:50 to 13:20
Auditorium VIII
Kari Lancaster

**buprenorphine
for opioid use
disorder: key
findings from a
longitudinal
qualitative
study**

11:50 to 13:20
Auditorium IV
Joanne Neale

**Alcohol Use
Disorder:
Implications
for Prevention
and Treatment**

11:50 to 13:20
Auditorium II
Jorge Martins

Oral presentation

**Identifying
harmful alcohol
use with
phosphatidyletha
16:0/18:1 in
patients with
suspected
severe injury**

11:50 to 13:20
Auditorium II
Benedicte Joergenrud

Oral presentation

**Adapting
Opioid
Therapy:
Transition from
Methadone to
Slow-Release
Morphine Amid
COVID-19
Supply Chain
Disruptions**

11:50 to 13:20
Auditorium IV
Artūras Barkus

Oral presentation

**Endgames:
Disease
eliminations
and their
politics**

11:50 to 13:20
Auditorium VIII
Tim Rhodes

Oral presentation

**VALIDATION OF
PLASMA
BIOMARKERS
FOR
PREDICTING
AND
PREVENTING
ALCOHOL-
ASSOCIATED
RISK OF
DEMENTIA:
PRELIMINARY
DATA**

11:50 to 13:20
Auditorium II
Fernando Rodriguez de
Fonseca

Oral presentation

**A Global
Perspective on**

Oral presentation

**A Holistic
Multi-**

Oral presentation

**A wastewater-
based**

Treatment Service Provision for Opioid Use Disorders

11:50 to 13:20
Auditorium III
Arash Khojasteh Zonoozi

Disciplinary Healthcare Pathway for Older Men who use Anabolic Androgenic Steroids

11:50 to 13:20
Room 1.08
Evelyn Hearne

approach to monitor shifting trends in illicit drugs consumption in Switzerland

11:50 to 13:20
Room 5A
Livia Andrani

Oral presentation

Cannabis policy and practice in Finland: from social media discussions to citizens initiatives

11:50 to 13:20
Room 1.08
Aleksi Hupli

Oral presentation

Clinicians' experience of providing heroin-assisted treatment: Key rewards and challenges

11:50 to 13:20
Room 5C
Rune Ellefsen

Oral presentation

Drink and be merry? The impact of alcohol and affective social cues on emotional contagion

11:50 to 13:20
Auditorium II
Rebecca Monk

Oral presentation

Drugs and climate change: knowledge gaps in monitoring environmental impacts of drugs

11:50 to 13:20
Room 1.08
Tim Surmont

Oral presentation

European Hair Drug Analysis Network - A pioneer study to investigate the use of NPS

Oral presentation

Fostering Community: A Mixed Method Analysis of Kosmicare's Mobile Drug

Oral presentation

Health-related quality of life trajectories of patients in heroin-assisted treatment

and NSO

11:50 to 13:20
Room 5A
Elisa Fornero

Checking Service in Lisbon, Portugal

11:50 to 13:20
Room 5C
Helena Valente

11:50 to 13:20
Auditorium III
Francesca Melis

Oral presentation

Impact of long- acting depot buprenorphine post-release from custody- Early findings from the Release Study

11:50 to 13:20
Auditorium IV
Adrian Dunlop

Oral presentation

Key challenges for alcohol epidemiology and alcohol control policy evaluation

11:50 to 13:20
Auditorium VI
Jürgen Rehm

Oral presentation

Legally grey? Drug checking perspectives in the CEECA region

11:50 to 13:20
Auditorium VI
Eliza Kurcevič

Oral presentation

Opioid disorder treatment outcomes — the OPTIMUS international consensus on evidence- based and patient- centred care

11:50 to 13:20
Auditorium III
Lucas Wiessing

Oral presentation

Perceptions of family physicians in Istanbul on e- cigarettes as smoking cessation aids

11:50 to 13:20
Room 1.08
Melis Selamoglu

Oral presentation

Prevention of hazardous substance use among refugees - digital tools for the workforce in refugee aid

11:50 to 13:20
Room 5C
Jonathan Uricher

Oral presentation

Public health for whom? Unpacking the assumptions and silences in Canada's public health approach to substance use.

11:50 to 13:20
Auditorium VI
Sophie Henderson

Oral presentation

Synthesis of multisource data for the development of an advanced dashboard to monitor illicit drugs markets

11:50 to 13:20
Room 5A
Pierre Esseiva

Oral presentation

The Costs and Harms of Substance Use in Canada: Key Trends from 2007 to 2022

11:50 to 13:20
Auditorium VI
Pam Kent

Oral presentation

The situation of Harm Reduction in Spain: a qualitative approach including PWUD

11:50 to 13:20
Room 5C
Ester Aranda

Oral presentation

Trends in use of medicines for opioid agonist treatment in Australia, 2013-2022

11:50 to 13:20
Auditorium III
Michael Farrell

Oral presentation

What can Portugal do to prevent be caught off guard again in the drug domain?

11:50 to 13:20
Room 5A
Alcina Correia

14:20

Oral presentation

Practical overview of management including naloxone dosing. Illustration with cases related to potent synthetic opioids, St Thomas' hospital, 2023.

14:20 to 15:50
Auditorium VIII

Oral presentation

Looking Ahead: Future Priorities for Cannabis Research, Public Education, and Prevention

14:20 to 15:50
Auditorium IV
Shea Wood

Oral presentation

Overview of the Cannabis Act and Cannabis Regulations

14:20 to 15:50
Auditorium IV
Robert Gabrys

Oral presentation

Post-mortem analytical findings and characteristics of the nitazene-

related deaths cases, Finland, 2023

14:20 to 15:50
Auditorium VIII
Kriikku Pirkko

Oral presentation

A Review of the Public Health and Safety Impacts of Cannabis of Legalization and Key Recommendations

14:20 to 15:50
Auditorium IV
Justine Renard

Oral presentation

Acute drug toxicity outbreak with nitazenes involved in prison setting and the community, La Réunion, France, June- July 2023

14:20 to 15:50
Auditorium VIII
Joris Guyon

Oral presentation

Acute nitazene- toxicity presentations to hospital emergency services, Dublin, Ireland, November 2023 outbreak

14:20 to 15:50
Auditorium VIII
Adrian Moughty

Oral presentation

Dynamic associations between anxiety and alcohol use from early adolescence to young adulthood.

14:20 to 15:50
Auditorium VII
Margot Peeters

Oral presentation

A mixed methods systematic review of interventions for women in the perinatal

Oral presentation

A randomized controlled trial of support programs for parents of treatment- refusing

Oral presentation

Associations between opioid agonist therapy exposure and chronic pain characteristics

**period, who
are dependent
on drugs**

14:20 to 15:50
Room 5B
Emma Smith

Oral presentation

**Cannabis use
disorder and
the brain: The
role of cross-
cultural
differences in
cannabis
attitudes**

14:20 to 15:50
Auditorium III
Janna Cousijn

**substance
using young
adults**

14:20 to 15:50
Auditorium VII
Ola Siljeholm

Oral presentation

**Community-
wide effects of
building a
resilient
community
healthcare
workforce**

14:20 to 15:50
Room 5C
Carol Jones

**among people
who inject
drugs**

14:20 to 15:50
Auditorium VI
Sasha Udhesister

Oral presentation

**Conceptualising
the right to
health in the
context of the
world drug
problem**

14:20 to 15:50
Auditorium VI
Alison Ritter

Oral presentation

**Differential
effects of left
and right
insula
inhibition on
craving and
cognitive
control in
regular
smokers**

14:20 to 15:50
Auditorium III
Mieke Schulte

Oral presentation

**Drug-related
deaths among
housed and
homeless
individuals in
the UK and the
USA**

14:20 to 15:50
Auditorium IV
Emmert Roberts

Oral presentation

**Drug-related
mortality
associated
with
gabapentinoid/
Z-drug co-
prescribing
among opioid-
agonist
treatment**

Oral presentation

**EXPERIENCES
OF DRUG
CONSUMPTION
ROOM
PROFESSIONALS**

14:20 to 15:50
Room 5C
Patricia Domingos Belo

Oral presentation

recipients

14:20 to 15:50
Auditorium IV
Megan Glancy

Female-specific trends and treatment needs for substance use disorder among homeless and at-risk females

14:20 to 15:50
Room 1.08
Anne Marie Carew

Oral presentation

Gender and drugs: Experiences of stigma/toxicophobias and narcofeminist narratives

14:20 to 15:50
Room 1.08
Marie Jauffret-Roustide

Oral presentation

High body mass index is prevalent in people with opioid use disorder in Northern England and increases risk of death

14:20 to 15:50
Auditorium IV
Caroline Copeland

Oral presentation

Innovation in caring for individuals experiencing polydrug use disorder: opportunities to understand multi-morbidities

14:20 to 15:50
Room 5C
Alexander Baldacchino

Oral presentation

International drug policy constellations: exploring the role of power and morality in international drug policy debates

14:20 to 15:50
Auditorium VI
Alex Stevens

Oral presentation

Peripheral endocannabinoids and related lipids in individuals with chronic non-medical prescription opioid use

14:20 to 15:50
Auditorium III
Sara Kroll

Oral presentation

Policy Responses to Drug-Related Deaths: The power of numbers?

14:20 to 15:50
Auditorium IV
Lena Eriksson

Oral presentation

Policy responses to drug-related deaths: Using

a Social Determinants of Health framework analysis to inform policy

14:20 to 15:50
Auditorium VI
Aileen O'Gorman

Oral presentation

**Pregnancy-
related
hospitalisation
among women
who inject
drugs in
Melbourne,
Australia**

14:20 to 15:50
Room 5B
Ashleigh Stewart

Oral presentation

**Squandered
sexenio:
applying drug
policy
constellations
to the failure
of marijuana
legalization in
Mexico (2018-
2024)**

14:20 to 15:50
Auditorium VI
Jonas von Hoffmann

Oral presentation

**Substance use
variation
among LGBTQ+
youth: stress,
resilience and
ecosystemic
intervention**

14:20 to 15:50
Auditorium VII
Julie-Christine Cotton

Oral presentation

**The care
pathways of
women who
use drugs in
the perinatal
period.
Findings of a
qualitative,
longitudinal
study**

14:20 to 15:50
Room 5B
Polly Radcliffe

Oral presentation

**The genetic
etiology of
cannabis use:
from twin
models to
genome-wide**

Oral presentation

**The perinatal
period as a
window of
opportunity for
change and
recovery? A**

Oral presentation

**Understanding
substance use
and affective
symptoms in
late
adolescents in**

association studies and beyond

14:20 to 15:50
Auditorium III
Karin J. H. Verweij

Oral presentation

Unveiling the Nexus of Addiction, Violence, and Risk: Generational Patterns in Female Populations

14:20 to 15:50
Room 1.08
Sabrina Molinaro

study of mothers and relatives' accounts

14:20 to 15:50
Room 5B
Sarah Vandewalle

Oral presentation

Vulnerabilities and agencies of women who use and sell drugs in Bordeaux and Montréal

14:20 to 15:50
Room 1.08
Sarah Perrin

an urban context: A network approach

14:20 to 15:50
Auditorium VII
Helle Larsen

Oral presentation

What do clinicians think about psychedelic assisted therapy? An Australian perspective.

14:20 to 15:50
Room 5C
Zachary Bryant

16:00

Oral presentation

Experiences of building a Prompt Response Network for emerging drugs of concern in Australia

16:00 to 17:30
Room 1.05
Brendan Clifford

Oral presentation

Psychosocial Care

16:00 to 17:30
Room 5C
Paul O'Brien

Oral presentation

Emerging Drug trends in Japan: rethinking prevention strategies

16:00 to 17:30
Room 1.05
Hironobu Fujiwara

Oral presentation

ACCS complexity of care provision

16:00 to 17:30
Room 5C
Jacob Krzanowski

Oral presentation

Socioeconomic differences in the real-world effectiveness of pharmacotherapy of alcohol-related health problems

16:00 to 17:30
Auditorium II
Devy Elling

Oral presentation

The promised endings and missed targets of global disease elimination

16:00 to 17:30
Auditorium VIII
Sarah Larney

Oral presentation

Are the key impacts being measured? Hepatitis C elimination in Australia

16:00 to 17:30
Auditorium VIII
Gregory Dore

Oral presentation

Estimating the global burden of alcohol's harm to others

16:00 to 17:30
Auditorium II
Anne-Marie Laslett

Oral presentation

Exploring Novel Psychoactive Substances Among Kazakhstan's Youth: A Focus on Emerging Trends and Risks

16:00 to 17:30
Room 1.05
Mariya Prilutskaya

Oral presentation

The Addiction Clinical Care Suite (ACCS): service outline and 2 year outcome data

16:00 to 17:30
Room 5C
John Archer

Oral presentation

Background and establishment of the Addiction Clinical Care Suite (ACCS): a comprehensive, multi-disciplinary inpatient addiction service in London

16:00 to 17:30
Room 5C
Shantelle Quashie

Oral presentation

Economic wealth, patterns of drinking, and alcohol-attributable disease burden

16:00 to 17:30
Auditorium II
Pol Rovira

Oral presentation

The case of Kratom: from traditional medical to recreational

use

16:00 to 17:30
Room 1.05
Vicknasingam Balasingam

Oral presentation

25 years of monitoring the Dutch cannabis market using chemical analysis: trends, developments and technical discussion

16:00 to 17:30
Room 1.08
Pieter Oomen

Oral presentation

A comparative analysis of state-controlled models for legal cannabis sales in Uruguay and Quebec (Canada)

16:00 to 17:30
Auditorium VI
Marta Rychert

Oral presentation

A national program to scale-up decentralized HCV point-of-care testing and treatment in Australia

16:00 to 17:30
Auditorium IV
Jason Grebely

Oral presentation

A provisional evaluation of Australia's medical cannabis framework

16:00 to 17:30
Auditorium VI
Myfanwy Graham

Oral presentation

Adverse childhood experiences and drug use in early adulthood: an analysis of the Growing Up in Ireland 1998 cohort

16:00 to 17:30
Room 5A
Deirdre Mongan

Oral presentation

Biography, age and temporality: understanding shifts in alcohol consumption over time among young abstainers

16:00 to 17:30
Room 5A
Amy Pennay

Oral presentation

Brorphine analogues as new psychoactive substances: in vitro and in vivo pharmacological characterization

16:00 to 17:30
Auditorium III
Marthe Vandeputte

Oral presentation

Consequences of cannabis legalization on use and health outcomes on the basis of international experiences

16:00 to 17:30
Auditorium VI
Uwe Verthein

Oral presentation

Dropout from addiction treatment: predictors, patient profiles, outcomes, and recommendations to improve care.

16:00 to 17:30
Auditorium VII
Marie-Josée Fleury

Oral presentation

Drug monitoring by samples seized at 2018, 2022 and 2023 BOOM festival editions

16:00 to 17:30
Room 1.08
Carla Filipa Ferreira

Oral presentation

Factors associated with cocaine use in late adolescence and young adulthood in the Growing Up in Ireland cohort study

16:00 to 17:30
Room 5A
Margaret Brennan

Oral presentation

HCV Community-led monitoring: from consultation to effective policy contributions

16:00 to 17:30
Auditorium IV
Lynn Jefferys
Joana Canedo

Oral presentation

In vitro cannabinoid activity-based screening of seized plant materials: a future-proof harm reduction strategy?

16:00 to 17:30
Auditorium III
Axelle Timmermann

Oral presentation

LECUCA: Analysis of Brazil's largest open drug scene using time-series cross-sectional survey data

16:00 to 17:30
Room 1.08
Clarice Madruga

Oral presentation

Modelling the impact of

Oral presentation

Neurotoxicity of synthetic

Oral presentation

Online Addictions

**scaling up of
HCV case
finding and
treatment for
people who
inject drugs in
England**

16:00 to 17:30
Auditorium IV
Zoe Ward

**cathinones:
Can
metabolism
play a role?**

16:00 to 17:30
Auditorium III
Alexandra Antunes

**Expert Group
of the
Pompidou
Group: Results
and
Recommendations**

16:00 to 17:30
Room 5B
Jann Schumacher

Oral presentation

Oral presentation

**Pharmacology
of 30
semisynthetic
cannabinoids -
and why
details matter
when
assessing the
harm potential
of seized drugs**

16:00 to 17:30
Auditorium III
Christophe Stove

**Pilot HCV Birth
Cohort
Screening in
UK Primary
Care using a
postal oral
fluid home
testing kit: the
HEPCAPP
StudyPP
STUDY**

16:00 to 17:30
Auditorium IV
Matt Hickman

Oral presentation

Oral presentation

Oral presentation

**Prevention
when exclusion
is lifted:
Intervention
models from
the New Swiss
Gambling Act**

16:00 to 17:30
Room 5B
Linda Elezi

**Risks and
harms
associated
with online
gaming and
gambling**

16:00 to 17:30
Room 5B
Eduarda Ferreira

**Same
Intentions,
Different
Outcomes:
Divergent
Paths and
Implementation
Gaps in
Cannabis
Legalization in
North America**

16:00 to 17:30
Auditorium VI
Ivana Obradovic

Oral presentation

Oral presentation

Oral presentation

Service user

The end of

The use of

**and Carer
perspective on
Treatment for
Co-Occurring
Mental Health
and Substance
Use Problems
(RECO Study)**

16:00 to 17:30
Auditorium VII
Elizabeth Hughes

**responsible
gambling**

16:00 to 17:30
Room 5B
Charles Livingstone

**patient-
reported
outcomes in
residential
alcohol &
drug services
in Belgium:
findings from
the OMER-BE
study**

16:00 to 17:30
Auditorium VII
Amine Zerrouk

Oral presentation

**Trends in illicit
and licit
substance use
across Spain -
A
comprehensive
three-year
wastewater-
based
epidemiology
study.**

16:00 to 17:30
Room 1.08
José Benito Quintana

Oral presentation

**Who is driving
under the
influence of
cannabis in
Germany?
Findings of a
large-scale
online survey**

16:00 to 17:30
Room 5A
Anna Schranz

17:50

Oral presentation

**Age-related
loss of
autonomy,
residential
instability and
alcohol use:
suggestions to
improve
intervention
and services**

17:50 to 19:20
Auditorium VI

Oral presentation

**Epidemiology
of injecting
drug use and
injection
related harms
among people
who are
incarcerated**

17:50 to 19:20
Auditorium IV
Louisa Degenhardt

Oral presentation

**Exploring
drinking
motives and
alcohol
consumption in
a UK LGBTQ+
population**

17:50 to 19:20
Auditorium II
Adam Qureshi

Oral presentation

Illustrating the Recovery Journey: Exploring Women's Alcohol Treatment Experiences Through Participant Drawings

17:50 to 19:20
Auditorium II
Juliette Allen

Oral presentation

Patient characteristics and treatment outcome predictors in older adults in routine care alcohol use disorder treatment

17:50 to 19:20
Auditorium VI
Silke Behrendt

Oral presentation

Investigating sex and gender differences in alcohol cue-reactivity: implications for treatment strategies?

17:50 to 19:20
Auditorium II
Anne Marije Kaag

Oral presentation

Working elements in interventions to reduce problematic alcohol use according to older adults: a realist evaluation

17:50 to 19:20
Auditorium VI
Fieke van den Bulck

Oral presentation

A systematic review examining how gender and sex are measured and reported in research on alcohol treatment

17:50 to 19:20
Auditorium II
Rodney Knight

Oral presentation

Acute drug-toxicity presentations involving polydrug use to Euro-DEN Plus sentinel hospitals in Europe from 2014 to 2022

17:50 to 19:20
Room 5B
Peter Heudtlass

Oral presentation

Cannabis liberalization is only associated with increased blunt use if states lack strong tobacco control

17:50 to 19:20
Room 5A
Brian Kelly

Oral presentation

Cocaine use on the rise - are politicians and city level services prepared for the emerging trend of crack cocaine?

17:50 to 19:20
Auditorium III
Else Kristin Utne Berg

Oral presentation

Context specific factors that impact on the optimal scale up of hepatitis C testing and treatment in the UK

17:50 to 19:20
Auditorium IV
Peter McCulloch

Oral presentation

Data collection on acute drug toxicity using the Euro-DEN plus model in countries bordering the European Union

17:50 to 19:20
Room 5B
Thomas Néfau

Oral presentation

Do minimum unit pricing policies reduce alcohol harms? A review of new evidence.

17:50 to 19:20
Room 5A
Cassandra Wright

Oral presentation

Dual diagnosis and their care pathways for help-seeking: a multi-center study from India

17:50 to 19:20
Auditorium VII
Abhishek Ghosh

Oral presentation

Impact of mental health on retention in OAT

17:50 to 19:20
Auditorium VII
Lucy Thi Tran

Oral presentation

Inpatient admissions in people with opioid dependence: a portuguese population-

Oral presentation

Intervention development of a nature-based programme for co-occurring mental health

**based
observational
retrospective
study**

17:50 to 19:20
Room 5B
José Miguel Paupério

**and substance
use problems.**

17:50 to 19:20
Auditorium VII
Wendy Masterton

Oral presentation

**Islands in the
stream: The
accessibility of
mental health
care for
persons with
substance use
problems in
Belgium**

17:50 to 19:20
Auditorium VII
Clara De Ruysscher

Oral presentation

**It is time to
take nitrous
oxide seriously**

17:50 to 19:20
Room 5C
Julaine Allan

Oral presentation

**Misuse of
psychoactive
medicines and
its harmful
consequences
in Portugal**

17:50 to 19:20
Auditorium VIII
Ana Araújo

Oral presentation

**Nangs in
Australia:
Investigating
nitrous oxide
use among
people who
regularly use
MDMA and/or
other illicit
stimulants**

17:50 to 19:20
Room 5C
Jodie Grigg

Oral presentation

**New
challenges for
outpatient
care: trends
from twenty
years of
monitoring
treatment**

Oral presentation

**Non-Fatal
Overdose: A
Decade-Long
Analysis of
Inner-City
Hospitals and
Nationwide
Trends Across**

Oral presentation

**Population
aging and
apparent
decline in
initiation of
injecting drug
use in
Australia**

demand in the city of Hamburg

17:50 to 19:20
Room 5C
Marcus Martens

Ireland (2011-2021)

17:50 to 19:20
Room 5B
Jo-Hanna Ivers

17:50 to 19:20
Room 5C
Olivia Price

Oral presentation

Pushing the limits of tobacco control; How far can the state go in order to save us from our sins

17:50 to 19:20
Room 5A
Karl Erik Lund

Oral presentation

Responding to the identification of nitazenes within the illicit diazepam market

17:50 to 19:20
Auditorium III
Josie Smith

Oral presentation

Socioeconomic risk factors for long-term prescription opioid use: A national registry-linkage study

17:50 to 19:20
Auditorium VIII
Ingvild Odsbu

Oral presentation

The development of a toolkit to support the elimination of viral hepatitis B and C in prisons

17:50 to 19:20
Auditorium IV
Erika Duffell

Oral presentation

The impact of alcohol taxation on alcohol-attributable health inequalities in the US: a microsimulation study

17:50 to 19:20
Room 5A
Carolin Kilian

Oral presentation

Towards elimination of hepatitis C in Oslo: cross-sectional prevalence studies in 2018, 2021, 2022 and 2023

17:50 to 19:20
Auditorium IV
Eirik Opheim

Oral presentation

Understanding Drug Use in a Dutch Prison: A Call for Improved Research and Care and Lessons learned

17:50 to 19:20
Auditorium III
Daan van der Gouwe

Oral presentation

Oral presentation

Oral presentation

Using intensive longitudinal data to investigate predictors of cannabis and opioid use among patients with chronic pain

17:50 to 19:20
Auditorium VIII
Johannes Thrul

Oral presentation

Words vs. strands: Does the concordance of self-reported and hair-analyzed substance use of young adults change over time?

17:50 to 19:20
Auditorium III
Clarissa Janousch

Fri 25 Oct

11:50

Oral presentation

Effectiveness of Machine Learning Based Adjustments to an eHealth Intervention Targeting at Risk Alcohol Use

11:50 to 13:20
Auditorium II
Matthijs Blankers

Oral presentation

Identification and treatment of AUD with the 15-method - Evaluating effectiveness of the method in Danish primary care

11:50 to 13:20
Auditorium II
Anette Søgaaard Nielsen

Oral presentation

Situation in Afghanistan: Opium cultivation and heroin production

11:50 to 13:20
Auditorium I
Angela Me

Oral presentation

Substance use patterns among young homicide offenders in Finland 2002-2022

11:50 to 13:20
Auditorium VIII
Anna Raeste

Oral presentation

Homicides

Oral presentation

Opium and

Oral presentation

An exploration

**committed by
criminal groups
involved in
Swedish drug
distribution**

11:50 to 13:20
Auditorium VIII
Kim Moeller

**heroin
production in
Southeast Asia**

11:50 to 13:20
Auditorium I
Bryce Pardo

**of drug
market, gun
violence and
sociodemographic
patterns in
Stockholm
Sweden and
the prediction
of gun violence**

11:50 to 13:20
Auditorium VIII
Mia-Maria Magnusson

Oral presentation

**Implications of
heroin
shortages in
Europe: the
emergence of
synthetic
opioids**

11:50 to 13:20
Auditorium I
Joanna Morais

Oral presentation

**Revisiting
Goldstein: A
New
Framework for
Understanding
Drug-Related
Violence in a
Globalised Era**

11:50 to 13:20
Auditorium VIII
Marieke Liem

Oral presentation

**Smartphone-
Delivered
Cognitive Bias
Modification
for Reducing
Harmful
Drinking
amongst
middle - older
age adults**

11:50 to 13:20
Auditorium II
Victoria Manning

Oral presentation

**The evolving
situation with
nitazenes in
Ireland**

11:50 to 13:20
Auditorium I
Eamon Keenan

Oral presentation

**Accidental
versus
intentional
drug overdose
deaths: a
national
register
linkage study**

11:50 to 13:20
Auditorium IV
Rebecca McDonald

Oral presentation

**Advancing
Harm
Reduction and
Saving Lives: A
Comprehensive
Evaluation of
Initiatives and
Outcomes in
Greece.**

11:50 to 13:20
Room 5A
Athanasios Theocharis

Oral presentation

An online

Oral presentation

Behind the

Oral presentation

Current

**survey of
cannabis users
and ex-users in
Ireland**

11:50 to 13:20
Room 5B
Philip James

**frontlines:
Exploring
mental well-
being and
burnout among
harm reduction
workers**

11:50 to 13:20
Room 1.07
Katie McCormick

**perspectives
on the
research and
medical use of
psychedelic
drugs for
alcohol
addiction
treatment**

11:50 to 13:20
Auditorium VI
Anton Gomez-Escolar

Oral presentation

**Development
and validation
of the
Problematic
Dating App Use
Scale
(PRODAS):
First results
from a sexual
minority cohort**

11:50 to 13:20
Auditorium III
Babette Lea Winter

Oral presentation

**Do Self-Report
Drug Use
Surveys
Produce the
Same Results
in Print and
Online Mode?
Findings from
a Dual Mode
Survey.**

11:50 to 13:20
Room 5B
Stelios Stylianou

Oral presentation

**Drug checking:
a harm
reduction
intervention to
address the
illicit drug
toxicity crisis
in a Canadian
setting**

11:50 to 13:20
Room 5A
Lianping Ti

Oral presentation

**Drug use in
French prisons.
Results of the
ESSPRI survey**

11:50 to 13:20
Room 5C
Caroline Protais

Oral presentation

**Drug-induced
deaths and
non-fatal
poisonings in
youth -
associations
with ACE and**

Oral presentation

**Illegal loot box
advertising on
social media:
an empirical
study using the
Meta and
TikTok ad**

Oral presentation

**Implementing
trauma-
focused
integrated
treatment for
women with
PTSD and**

psychiatric morbidity

11:50 to 13:20
Auditorium IV
Karoliina Karjalainen

Oral presentation

Needs & Modalities of Drug checking for Drug Users: Perspective of People with Lived Experience and Service Providers.

11:50 to 13:20
Room 5A
Jean-Sébastien Fallu

Oral presentation

Predictors of untreated remission of Internet Use Disorder in a sample of adolescents and young adults

11:50 to 13:20

transparency repositories

11:50 to 13:20
Auditorium III
Leon Y. Xiao

Oral presentation

Online approach and characteristics of the hidden population with substance use disorder that doesn't reach treatment

11:50 to 13:20
Room 5B
Ilias Paraskevopoulos

Oral presentation

Prevalence of Benzodiazepine Prescription Prior to Overdose Deaths Compared to Toxicological Findings

11:50 to 13:20

substance use disorder in Australia

11:50 to 13:20
Auditorium VII
Shalini Arunogiri

Oral presentation

Overdoses in Healthcare Workers: A thematic framework analysis of coroner reports

11:50 to 13:20
Room 1.07
Thikra Algahtani

Oral presentation

Posttraumatic stress disorder treatment in patients with co- substance use disorders: a randomized clinical trial

11:50 to 13:20
Auditorium VII
Marleen de Waal

Oral presentation

Prison-based treatment needs for people with a history of substance use disorder: A nationwide cohort study

11:50 to 13:20

Auditorium III
Lasse Schmidt

Auditorium IV
Anna Armika Tussilago
Nyman

Room 5C
Birgitte Thylstrup

Oral presentation

**Psychedelic
therapy in the
treatment of
addiction: the
past, present
and future**

11:50 to 13:20
Auditorium VI
Rayyan Zafar

Oral presentation

**Qualitative
examination of
coping
motives,
microaggression
and
psychological
distress among
bisexual+
women
survivors**

11:50 to 13:20
Auditorium VII
Gabriela Lopez

Oral presentation

**Relationship
between
parenting
styles and
problematic
Internet use**

11:50 to 13:20
Auditorium III
Antonio Raya

Oral presentation

**Substance use
and
psychological
states in
imprisoned
population in
Greece—Key
findings from a
recent
nationwide
survey**

11:50 to 13:20
Room 5C
Ioulia Bafi

Oral presentation

**Suicide in
people
prescribed
opioid-agonist
therapy (OAT)
in Scotland,
2011-2020: a
national
retrospective
cohort study.**

11:50 to 13:20
Auditorium IV
Rosalyn Fraser

Oral presentation

**The feasibility,
meaningfulness,
and
preliminary
effect of
trauma
focused
treatment for
drug use
disorders in
Denmark**

11:50 to 13:20
Auditorium VII
Sidsel Karsberg

Oral presentation

**The Mental
Health
Challenges
Faced by Harm
Reduction Staff**

11:50 to 13:20
Room 1.07
Laoise Darragh

Oral presentation

**The old kid in
the block:
Unpacking**

signals of increased availability and use of ketamine

11:50 to 13:20
Auditorium VI
Rita Jorge

Oral presentation

The Pharmacological Management of Ketamine Use Disorder: A Systematic Review

11:50 to 13:20
Auditorium VI
Emmert Roberts

Oral presentation

Vicarious Trauma Among Nurses Working in Addiction Services and the Role of Leadership: A European Mixed Methods Study

11:50 to 13:20
Room 1.07
K. Nicki Annunziata

Oral presentation

What can we learn about poly-drug use among frequent cannabis users? results from the European Web Survey on Drugs

11:50 to 13:20
Room 5B
Davide Fortin

Oral presentation

What you might do versus what you actually do: measuring participant drug behaviours in drug checking services

11:50 to 13:20
Room 5A
Anna Olsen

14:20

Oral presentation

Gambling and global public

Oral presentation

Update on the situation in the

Oral presentation

Work related cocaine use:

**health:
recommendation
from the
Lancet Public
Health
Commission on
Gambling**

14:20 to 15:50
Auditorium I
Heather Wardle

Oral presentation

**Measuring
Gambling
Harms: a
systematic
review and
review of
challenges**

14:20 to 15:50
Auditorium I
Louisa Degenhardt

**Netherlands
(tbc)**

14:20 to 15:50
Auditorium VIII
Margriet Van Laar

Oral presentation

**Cannabis law
reform in
Switzerland:
purpose,
opportunities,
and risks of
local pilot
projects**

14:20 to 15:50
Auditorium VIII
Frank Zobel

Oral presentation

**The Workplace
as a “Co-
Therapist”**

14:20 to 15:50
Auditorium II
Camilla Lynne Bakkeng

Oral presentation

**Gambling in
Low and
Middle Income
Countries:
evidence from
Indonesia and
Sub-Saharan
Africa**

14:20 to 15:50
Auditorium I
Kristiana Siste

**prevalence and
interventions**

14:20 to 15:50
Auditorium II
Marie-Claire Lambrechts

Oral presentation

**Issues of
transport,
driving safety
&
intoxication for
opioid agonist
treatment
clients in New
South Wales,
Australia**

14:20 to 15:50
Auditorium VI
Daniel Winter

Oral presentation

**Cannabis law
reform in
Germany: a
rocky road to a
partial
legalisation**

14:20 to 15:50
Auditorium VIII
Jakob Manthey

Oral presentation

**Individual
agreements for
recovery from
substance
misuse.
Employees’
response and
experience of
regulatory
aspects.**

14:20 to 15:50

Oral presentation

Physical conditions and associated health service utilization among individuals with substance-related disorders

14:20 to 15:50
Auditorium VI
Christophe Huynh

Oral presentation

A healthy work environment for Eastern European migrant workers in The Netherlands

14:20 to 15:50
Auditorium II
Desirée Spronk

Oral presentation

Cannabis law reform in Luxembourg: first observations after its change among recreational cannabis users and non-users

14:20 to 15:50
Auditorium VIII
Nadine Berndt

Oral presentation

Global legislative trends in gambling policy

14:20 to 15:50
Auditorium I
Virve Marionneau

Oral presentation

The effect of substance use disorders on vaccine uptake, acceptance, and adherence: a global systematic review

14:20 to 15:50
Auditorium VI
Eva Maria Havelka

Oral presentation

Out of treatment drug and alcohol users in England: ‘Unmet Treatment Need’?

14:20 to 15:50
Auditorium VI
Charlie Lloyd

Oral presentation

Pathways into individual substance misuse recovery agreement in the workplace

14:20 to 15:50
Auditorium II
Janne Scheffels

Oral presentation

The Commercial Determinants of Gambling Harms

14:20 to 15:50
Auditorium I
Gerda Reith

Oral presentation

Addressing Alcohol-Related Risks among Individuals with Disabilities in Sports: A Swiss Perspective

14:20 to 15:50
Room 5A
Nikolai Kiselev

Oral presentation

Are Take-Home Naloxone kits available at witnessed overdose events - a European Naloxone Outcome Research Study

14:20 to 15:50
Auditorium IV
Teodora Dascal

Oral presentation

Culturally safe addiction services: An integrated circle of care for homeless Indigenous peoples in Montréal, Canada

14:20 to 15:50
Room 5A
Jessica Neicun

Oral presentation

Development, implementation and liquidation of a national Danish Train-the-Trainer system 2010 - 2023

14:20 to 15:50
Auditorium IV
Henrik Thiesen

Oral presentation

Does Variation in Local Policy Mediate the Impact of Legal Cannabis Markets on Adolescent Cannabis Use?

14:20 to 15:50
Auditorium III
Rosalie Liccardo Pacula

Oral presentation

Drug and Alcohol Related Intoxication

Oral presentation

Evaluating a pilot intervention development

Oral presentation

Impact of Precursor Control on Drug Markets:

Among Young Adolescents in Palestine

14:20 to 15:50
Auditorium III
Saed Bilbaisi

programme utilising respiratory monitoring to prevent drug-related deaths

14:20 to 15:50
Auditorium IV
Kristina Hnízdllová

An Expanded and Updated Systematic Review

14:20 to 15:50
Room 5B
Luca Giommoni

Oral presentation

Interventions to reduce harms related to drug use among people who experience incarceration: A systematic review

14:20 to 15:50
Auditorium VII
Christel Macdonald

Oral presentation

New processes of normalisation? Understanding changes in young people's drug use in the UK.

14:20 to 15:50
Auditorium III
Harry Sumnall

Oral presentation

PRS20: drug use and perceived mental health concerns among people living in prison in the Grand-Duchy of Luxembourg

14:20 to 15:50
Auditorium VII
Tom Kugener

Oral presentation

Radio theater-based prison artistic intervention: a mixed-method evaluation

14:20 to 15:50
Auditorium VII
Isabel Silva

Oral presentation

Spatial analysis of drug seizure events in the Golden Triangle: Findings from UNODC's Drug Monitoring

Platform

14:20 to 15:50
Room 5B
Bryce Pardo

Oral presentation

Substance Use, Well-being, and Spiking among LGBTIQ+ and Non-LGBTIQ+ Nightlife Patrons: A Cross-Sectional Survey

14:20 to 15:50
Room 5A
Ruben van Beek

Oral presentation

The (cost-)effectiveness of contingency management for cannabis use disorder in youth: A randomized controlled trial

14:20 to 15:50
Auditorium III
Eva Garssen

Oral presentation

The impact of the 2022 ban on drug production in Afghanistan

14:20 to 15:50
Room 5B
Angela Me

Oral presentation

The impacts of cannabis legalization in the Americas: Insights from a systematic review

14:20 to 15:50
Room 5B
Elle Wadsworth

Oral presentation

The multidimensional needs and integrated service utilization patterns of youth using non-medical prescription opioids

14:20 to 15:50
Room 5A
Kirsten Marchand

Oral presentation

Who reports witnessing an opioid overdose? : Findings from the European naloxone outcome research study (NalPORS)

14:20 to 15:50
Auditorium IV
Clare Mackie